More than 97,000 patients who receive antiretroviral drugs for the treatment of HIV in Mexico guarantee the delivery of their medicines, according to the National Center for Prevention and Control of HIV and AIDS (CENSIDA).
The agency also reported that there was enough stock to take care of people diagnosed with the disease, pointing out that the process of buying these drugs for 2019 "did not affect the debt or the health of people they receive."
He pointed out that, while the purchase process is still open, they carry out the process of redistribution of medicines, assignment of treatment programs, and information on prescribing, modifying and delivering medicines.
Likewise, he said, there are mechanisms to maintain antiretroviral supplies across the country, either through direct purchases, open international public tenders, or support from other public health institutions.
CENSIDA has repeated that the drugs purchased through the tender were covered by the beginning of June 2019.
While in the case of patent medicines there is enough stock to satisfy demand by the beginning of May 2019.
He said it is expected this month to launch the first delivery of antiretroviral drugs, received by a direct reward, in order to avoid the treatment of HIV-infected patients being treated at the Ministry of Health.
Likewise, it was announced that a contract for the purchase of antiretroviral drugs for the period 2018-2019 was concluded on March 31. Years through the Disaster Recovery Fund.
In Mexico, according to Censida, between 1963 and March 2018 196,227 cases were reported in the country.
By 2017, coverage in the country was 65% in diagnosis, 61% in treatment and 51% in the control of viruses, and 80% of diagnosed persons are expected to reach in the next few years, closer to 90 t -90 -90 World Health Organization (WHO).